- Home
- OPBK vs NYXH Comparison
OPBK vs NYXH Comparison
Compare OPBK & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPBK
- NYXH
- Stock Information
- Founded
- OPBK 2005
- NYXH 2009
- Country
- OPBK United States
- NYXH Belgium
- Employees
- OPBK N/A
- NYXH N/A
- Industry
- OPBK Major Banks
- NYXH Medical/Dental Instruments
- Sector
- OPBK Finance
- NYXH Health Care
- Exchange
- OPBK Nasdaq
- NYXH Nasdaq
- Market Cap
- OPBK 204.6M
- NYXH 231.0M
- IPO Year
- OPBK 2018
- NYXH 2021
- Fundamental
- Price
- OPBK $14.54
- NYXH $6.19
- Analyst Decision
- OPBK Hold
- NYXH Strong Buy
- Analyst Count
- OPBK 1
- NYXH 3
- Target Price
- OPBK $15.50
- NYXH $15.00
- AVG Volume (30 Days)
- OPBK 44.3K
- NYXH 159.1K
- Earning Date
- OPBK 10-23-2025
- NYXH 08-18-2025
- Dividend Yield
- OPBK 3.40%
- NYXH N/A
- EPS Growth
- OPBK 8.15
- NYXH N/A
- EPS
- OPBK 1.48
- NYXH N/A
- Revenue
- OPBK $84,078,000.00
- NYXH $5,793,306.00
- Revenue This Year
- OPBK $22.05
- NYXH $144.57
- Revenue Next Year
- OPBK $10.50
- NYXH $244.36
- P/E Ratio
- OPBK $9.54
- NYXH N/A
- Revenue Growth
- OPBK 9.17
- NYXH 2.94
- 52 Week Low
- OPBK $10.43
- NYXH $5.55
- 52 Week High
- OPBK $18.57
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- OPBK 65.13
- NYXH 38.74
- Support Level
- OPBK $14.10
- NYXH $6.07
- Resistance Level
- OPBK $14.37
- NYXH $6.47
- Average True Range (ATR)
- OPBK 0.37
- NYXH 0.42
- MACD
- OPBK 0.08
- NYXH -0.01
- Stochastic Oscillator
- OPBK 82.23
- NYXH 19.01
About OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.